Clinical features and risk factors for early relapse of pediatric ulcerative colitis

Objective: To investigate the clinical features of pediatric ulcerative colitis (UC) and analyze the risk factors of disease relapse. Methods: The clinical data of 79 children with UC diagnosed in Beijing Children's Hospital, Capital Medical University from January 2016 to February 2021 were re...

Ausführliche Beschreibung

Bibliographische Detailangaben
Veröffentlicht in:Zhonghua er ke za zhi = Chinese journal of pediatrics. - 1960. - 60(2022), 7 vom: 02. Juli, Seite 660-665
1. Verfasser: Guan, D X (VerfasserIn)
Weitere Verfasser: Wu, J, Zhang, J, Guo, S, Yu, F H, Zhou, J, Wang, G L, Xu, X W
Format: Online-Aufsatz
Sprache:Chinese
Veröffentlicht: 2022
Zugriff auf das übergeordnete Werk:Zhonghua er ke za zhi = Chinese journal of pediatrics
Schlagworte:Journal Article
LEADER 01000naa a22002652 4500
001 NLM342892118
003 DE-627
005 20231226015145.0
007 cr uuu---uuuuu
008 231226s2022 xx |||||o 00| ||chi c
024 7 |a 10.3760/cma.j.cn112140-20220401-00271  |2 doi 
028 5 2 |a pubmed24n1142.xml 
035 |a (DE-627)NLM342892118 
035 |a (NLM)35768353 
040 |a DE-627  |b ger  |c DE-627  |e rakwb 
041 |a chi 
100 1 |a Guan, D X  |e verfasserin  |4 aut 
245 1 0 |a Clinical features and risk factors for early relapse of pediatric ulcerative colitis 
264 1 |c 2022 
336 |a Text  |b txt  |2 rdacontent 
337 |a ƒaComputermedien  |b c  |2 rdamedia 
338 |a ƒa Online-Ressource  |b cr  |2 rdacarrier 
500 |a Date Completed 01.07.2022 
500 |a Date Revised 01.07.2022 
500 |a published: Print 
500 |a Citation Status MEDLINE 
520 |a Objective: To investigate the clinical features of pediatric ulcerative colitis (UC) and analyze the risk factors of disease relapse. Methods: The clinical data of 79 children with UC diagnosed in Beijing Children's Hospital, Capital Medical University from January 2016 to February 2021 were retrospectively analyzed. They were divided into early relapse group and non-early relapse group according to the clinical relapse within 12 months after diagnosis. T-test, rank sum test, χ2 test or Fisher's exact test were used to compare the variables between the 2 groups, including the clinical features, laboratory examination results and treatments. The Logistic regression was used to analyze the risk factors of early relapse. The cumulative relapse rate during follow-up was calculated by Kaplan-Meier method. Results: Among the 79 UC children, 46 were males and 33 were females, and the age of onset was 10.6 (6.4, 12.7) years. The children were mainly characterized by extensive disease (E3) and pancolitis (E4) (51/79, 65%), moderate to severe activity (48/79, 61%) and moderate to severe inflammation of colonic mucosa (71/79, 90%). Thirty-eight (48%) patients had atypical phenotype and 17 (22%) had extraintestinal manifestations. The follow-up period was 43.9 (22.8, 61.3) months, and of the 41 patients rechecked with colonoscopy, 7 (17%) had disease progression. According to Kaplan-Meier analysis, the cumulative relapse rate of the 79 cases at 3 months, 6 months, 1 year and 2 years after diagnosis were 27% (21/79), 47% (37/79), 57% (45/79) and 73% (53/73), respectively. There were 45 children (57%) in early relapse group and 34 (43%) in non-early relapse group. In early relapse group, hemoglobin and mucosal healing rate were both significantly lower (105 (87, 122) vs. 120 (104, 131) g/L, 28% (7/25) vs. 7/9, Z=-2.38, χ²=4.87, both P<0.05). The rate of steroid-dependent, E3 and step-up therapy during the induction period were all significantly higher than those in non-early relapse group (11/19 vs. 1/12, 24% (11/45) vs. 6% (2/34), 29% (13/45) vs. 6% (2/34), χ²=5.67, 4.85, 6.66, all P<0.05). Multivariate Logistic regression analysis showed that extraintestinal manifestations (OR=4.33, 95%CI 1.05-17.83), E3 (OR=8.27, 95%CI 1.47-46.46) and step-up therapy during the induction period (OR=5.58, 95%CI 1.01-30.77) were independent risk factors for early relapse. Conclusions: Pediatric UC is usually extensive and severe, with atypical phenotype, a high rate of relapse and a risk of disease progression. Extraintestinal manifestations, E3 and step-up therapy during the induction period are independent risk factors for early relapse 
650 4 |a Journal Article 
700 1 |a Wu, J  |e verfasserin  |4 aut 
700 1 |a Zhang, J  |e verfasserin  |4 aut 
700 1 |a Guo, S  |e verfasserin  |4 aut 
700 1 |a Yu, F H  |e verfasserin  |4 aut 
700 1 |a Zhou, J  |e verfasserin  |4 aut 
700 1 |a Wang, G L  |e verfasserin  |4 aut 
700 1 |a Xu, X W  |e verfasserin  |4 aut 
773 0 8 |i Enthalten in  |t Zhonghua er ke za zhi = Chinese journal of pediatrics  |d 1960  |g 60(2022), 7 vom: 02. Juli, Seite 660-665  |w (DE-627)NLM136249191  |x 0578-1310  |7 nnns 
773 1 8 |g volume:60  |g year:2022  |g number:7  |g day:02  |g month:07  |g pages:660-665 
856 4 0 |u http://dx.doi.org/10.3760/cma.j.cn112140-20220401-00271  |3 Volltext 
912 |a GBV_USEFLAG_A 
912 |a SYSFLAG_A 
912 |a GBV_NLM 
912 |a GBV_ILN_11 
912 |a GBV_ILN_20 
912 |a GBV_ILN_22 
912 |a GBV_ILN_24 
912 |a GBV_ILN_31 
912 |a GBV_ILN_39 
912 |a GBV_ILN_40 
912 |a GBV_ILN_50 
912 |a GBV_ILN_61 
912 |a GBV_ILN_65 
912 |a GBV_ILN_69 
912 |a GBV_ILN_70 
912 |a GBV_ILN_72 
912 |a GBV_ILN_120 
912 |a GBV_ILN_130 
912 |a GBV_ILN_227 
912 |a GBV_ILN_244 
912 |a GBV_ILN_285 
912 |a GBV_ILN_294 
912 |a GBV_ILN_350 
912 |a GBV_ILN_665 
912 |a GBV_ILN_813 
951 |a AR 
952 |d 60  |j 2022  |e 7  |b 02  |c 07  |h 660-665